3 - 6 મહિના માટે શ્રેષ્ઠ મ્યુચ્યુઅલ ફંડ

Updated on July 27, 2026 , 112293 views

3 થી 6 મહિનાના ટૂંકા ગાળા માટે, તમે ક્યાં તો તમારા પૈસા પાર્ક કરી શકો છોપ્રવાહી મ્યુચ્યુઅલ ફંડ અથવા અલ્ટ્રા શોર્ટ ટર્મડેટ મ્યુચ્યુઅલ ફંડ. પ્રવાહીમ્યુચ્યુઅલ ફંડ સામાન્ય રીતે સરકારી સિક્યોરિટીઝમાં રોકાણ કરો અને 3 મહિના સુધીની ડિપોઝિટના પ્રમાણપત્ર.

જો કે જો કોઈ વધુ વળતર માટે જોખમ લેવા આતુર હોય તો નીચે આપેલા કેટલાક વિકલ્પો જોઈ શકે છે

ટોચના 5 હોટ મ્યુચ્યુઅલ ફંડ્સ 3 મહિના

નીચે યાદી છેશ્રેષ્ઠ મ્યુચ્યુઅલ ફંડ ચોખ્ખી અસ્કયામતો ધરાવે છે100 કરોડ અને છેલ્લા 3 મહિનામાં શ્રેષ્ઠ વળતર આપ્યું છે.

1. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

Upper mid AUM (₹4,998 Cr).
Established history (21+ yrs).
Rating: 2★ (lower mid).
Risk profile: High.
5Y return: 17.42% (top quartile).
3Y return: 23.05% (lower mid).
1Y return: 15.20% (top quartile).
Alpha: 2.23 (lower mid).
Sharpe: 0.59 (top quartile).
Information ratio: -0.17 (lower mid).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Sun Pharmaceuticals Industries Ltd (~11.0%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund Growth
Launch Date	31 Dec 04
NAV (29 Jul 26)	₹512.59 ↑ 6.51 (1.29 %)
Net Assets (Cr)	₹4,998 on 30 Jun 26
Category	Equity - Sectoral
AMC	SBI Funds Management Private Limited
Rating	☆☆
Risk	High
Expense Ratio	1.97
Sharpe Ratio	0.59
Information Ratio	-0.17
Alpha Ratio	2.23
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,662
30 Jun 23	₹11,165
30 Jun 24	₹15,491
30 Jun 25	₹18,739
30 Jun 26	₹21,357

SBI Healthcare Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	4.7%
3 Month	17%
6 Month	27.4%
1 Year	15.2%
3 Year	23%
5 Year	17.4%
10 Year
15 Year
Since launch	15.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-3.5%
2024	42.2%
2023	38.2%
2022	-6%
2021	20.1%
2020	65.8%
2019	-0.5%
2018	-9.9%
2017	2.1%
2016	-14%

Fund Manager information for SBI Healthcare Opportunities Fund

Name	Since	Tenure
Tanmaya Desai	1 Jun 11	15.09 Yr.

Data below for SBI Healthcare Opportunities Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	88.67%
Basic Materials	8.82%

Asset Allocation

Asset Class	Value
Cash	2.45%
Equity	97.49%
Debt	0.06%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Dec 17 \| SUNPHARMA	11%	₹504 Cr	2,800,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	7%	₹300 Cr	450,000
Acutaas Chemicals Ltd (Basic Materials) Equity, Since 30 Jun 24 \| 543349	6%	₹282 Cr	900,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Jan 26 \| APOLLOHOSP	5%	₹245 Cr	300,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 21 \| MAXHEALTH	5%	₹217 Cr	2,250,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Mar 26 \| AUROPHARMA	4%	₹178 Cr	1,250,000 ↑ 250,000
Aster DM Healthcare Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 24 \| ASTERDM	4%	₹175 Cr	2,400,000
Laurus Labs Ltd (Healthcare) Equity, Since 31 Aug 23 \| LAURUSLABS	4%	₹163 Cr	1,200,000
Biocon Ltd (Healthcare) Equity, Since 30 Nov 24 \| BIOCON	4%	₹161 Cr	3,750,000
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Jun 21 \| TORNTPHARM	3%	₹159 Cr	360,000

2. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

Bottom quartile AUM (₹1,308 Cr).
Oldest track record among peers (27 yrs).
Rating: 1★ (bottom quartile).
Risk profile: High.
5Y return: 15.05% (lower mid).
3Y return: 23.43% (top quartile).
1Y return: 12.09% (lower mid).
Alpha: 2.15 (bottom quartile).
Sharpe: 0.58 (upper mid).
Information ratio: 0.20 (upper mid).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Sun Pharmaceuticals Industries Ltd (~8.9%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund Growth
Launch Date	28 Jun 99
NAV (29 Jul 26)	₹335.233 ↑ 4.62 (1.40 %)
Net Assets (Cr)	₹1,308 on 30 Jun 26
Category	Equity - Sectoral
AMC	UTI Asset Management Company Ltd
Rating	☆
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.58
Information Ratio	0.2
Alpha Ratio	2.15
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,478
30 Jun 23	₹10,006
30 Jun 24	₹14,264
30 Jun 25	₹17,337
30 Jun 26	₹19,764

UTI Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹447,579.
Net Profit of ₹147,579 Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	3.9%
3 Month	14.6%
6 Month	24.8%
1 Year	12.1%
3 Year	23.4%
5 Year	15.1%
10 Year
15 Year
Since launch	15%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-3.1%
2024	42.9%
2023	38.2%
2022	-12.3%
2021	19.1%
2020	67.4%
2019	1.2%
2018	-7.5%
2017	6.2%
2016	-9.7%

Fund Manager information for UTI Healthcare Fund

Name	Since	Tenure
Kamal Gada	2 May 22	4.17 Yr.

Data below for UTI Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	94.45%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 06 \| SUNPHARMA	9%	₹108 Cr	600,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	5%	₹59 Cr	88,814 ↑ 28,076
Ajanta Pharma Ltd (Healthcare) Equity, Since 31 Jul 17 \| AJANTPHARM	5%	₹57 Cr	195,295 ↓ -41,216
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	4%	₹48 Cr	215,251
Lupin Ltd (Healthcare) Equity, Since 28 Feb 25 \| LUPIN	4%	₹46 Cr	203,834 ↓ -6,166
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Apr 21 \| APOLLOHOSP	4%	₹43 Cr	53,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 28 Feb 18 \| DRREDDY	3%	₹38 Cr	290,000
Caplin Point Laboratories Ltd (Healthcare) Equity, Since 31 Dec 23 \| CAPLIPOINT	3%	₹37 Cr	185,000 ↑ 39,847
Alkem Laboratories Ltd (Healthcare) Equity, Since 31 May 21 \| ALKEM	3%	₹37 Cr	68,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Dec 20 \| FORTIS	3%	₹37 Cr	400,000

3. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Research Highlights for TATA India Pharma & Healthcare Fund

Bottom quartile AUM (₹1,455 Cr).
Established history (10+ yrs).
Not Rated.
Risk profile: High.
5Y return: 14.11% (bottom quartile).
3Y return: 19.49% (bottom quartile).
1Y return: 8.02% (bottom quartile).
Alpha: -7.90 (bottom quartile).
Sharpe: 0.16 (bottom quartile).
Information ratio: -0.61 (bottom quartile).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Sun Pharmaceuticals Industries Ltd (~9.4%).

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund Growth
Launch Date	28 Dec 15
NAV (29 Jul 26)	₹33.7302 ↑ 0.32 (0.97 %)
Net Assets (Cr)	₹1,455 on 30 Jun 26
Category	Equity - Sectoral
AMC	Tata Asset Management Limited
Rating	Not Rated
Risk	High
Expense Ratio	2.17
Sharpe Ratio	0.16
Information Ratio	-0.61
Alpha Ratio	-7.9
Min Investment	5,000
Min SIP Investment	150
Exit Load	0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,951
30 Jun 23	₹10,628
30 Jun 24	₹15,238
30 Jun 25	₹17,550
30 Jun 26	₹18,791

TATA India Pharma & Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	5.3%
3 Month	12.5%
6 Month	19.4%
1 Year	8%
3 Year	19.5%
5 Year	14.1%
10 Year
15 Year
Since launch	12.2%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-4.9%
2024	40.4%
2023	36.6%
2022	-8%
2021	19.1%
2020	64.4%
2019	5.5%
2018	-2.6%
2017	4.7%
2016	-14.7%

Fund Manager information for TATA India Pharma & Healthcare Fund

Name	Since	Tenure
Rajat Srivastava	16 Sep 24	1.79 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	93.6%
Basic Materials	3.96%
Consumer Defensive	1.35%
Financial Services	0.4%

Asset Allocation

Asset Class	Value
Cash	0.7%
Equity	99.3%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Jan 16 \| SUNPHARMA	9%	₹130 Cr	723,130
HealthCare Global Enterprises Ltd (Healthcare) Equity, Since 31 Dec 18 \| HCG	6%	₹81 Cr	1,276,727 ↑ 15,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	6%	₹80 Cr	120,600
Abbott India Ltd (Healthcare) Equity, Since 30 Sep 25 \| ABBOTINDIA	5%	₹75 Cr	27,953
Cipla Ltd (Healthcare) Equity, Since 30 Apr 20 \| CIPLA	5%	₹72 Cr	512,754
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Jul 25 \| MAXHEALTH	5%	₹67 Cr	690,488
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Dec 16 \| APOLLOHOSP	5%	₹63 Cr	77,345 ↑ 6,861
Rainbow Childrens Medicare Ltd (Healthcare) Equity, Since 31 Jul 25 \| 543524	5%	₹63 Cr	454,338 ↑ 7,205
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 31 Aug 18 \| DRREDDY	4%	₹56 Cr	428,116 ↑ 54,652
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	4%	₹52 Cr	220,018

4. Invesco India Growth Opportunities Fund

(Erstwhile Invesco India Growth Fund)

The investment objective of the Scheme is to generate long-term capital growth from a diversified portfolio of predominantly equity and equity-related securities. However, there can be no assurance that the objectives of the scheme will be achieved.

Research Highlights for Invesco India Growth Opportunities Fund

Highest AUM (₹11,164 Cr).
Established history (18+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 17.38% (upper mid).
3Y return: 23.40% (upper mid).
1Y return: 8.77% (bottom quartile).
Alpha: 6.78 (upper mid).
Sharpe: 0.12 (bottom quartile).
Information ratio: 1.15 (top quartile).
Top sector: Financial Services.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Max Healthcare Institute Ltd Ordinary Shares (~6.8%).

Below is the key information for Invesco India Growth Opportunities Fund

Invesco India Growth Opportunities Fund Growth
Launch Date	9 Aug 07
NAV (29 Jul 26)	₹110.42 ↑ 0.98 (0.90 %)
Net Assets (Cr)	₹11,164 on 30 Jun 26
Category	Equity - Large & Mid Cap
AMC	Invesco Asset Management (India) Private Ltd
Rating	☆☆☆☆☆
Risk	Moderately High
Expense Ratio	1.82
Sharpe Ratio	0.12
Information Ratio	1.15
Alpha Ratio	6.78
Min Investment	5,000
Min SIP Investment	100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹9,616
30 Jun 23	₹12,058
30 Jun 24	₹18,524
30 Jun 25	₹21,406
30 Jun 26	₹22,689

Invesco India Growth Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for Invesco India Growth Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	2.4%
3 Month	11.2%
6 Month	16.1%
1 Year	8.8%
3 Year	23.4%
5 Year	17.4%
10 Year
15 Year
Since launch	13.5%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	4.7%
2024	37.5%
2023	31.6%
2022	-0.4%
2021	29.7%
2020	13.3%
2019	10.7%
2018	-0.2%
2017	39.6%
2016	3.3%

Fund Manager information for Invesco India Growth Opportunities Fund

Name	Since	Tenure
Aditya Khemani	9 Nov 23	2.64 Yr.

Data below for Invesco India Growth Opportunities Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Financial Services	26.21%
Health Care	18.9%
Industrials	18.79%
Consumer Cyclical	17.87%
Real Estate	7.6%
Basic Materials	4.07%
Technology	2.71%
Communication Services	1.71%
Utility	1.37%

Asset Allocation

Asset Class	Value
Cash	0.76%
Equity	99.23%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 30 Nov 22 \| MAXHEALTH	7%	₹687 Cr	7,118,724 ↑ 170,000
Eternal Ltd (Consumer Cyclical) Equity, Since 30 Jun 23 \| ETERNAL	7%	₹684 Cr	27,307,479 ↑ 2,577,787
InterGlobe Aviation Ltd (Industrials) Equity, Since 31 Mar 24 \| INDIGO	6%	₹654 Cr	1,484,863 ↑ 95,086
ICICI Bank Ltd (Financial Services) Equity, Since 31 Dec 15 \| ICICIBANK	6%	₹646 Cr	5,141,398 ↑ 511,565
Sai Life Sciences Ltd (Healthcare) Equity, Since 31 Dec 24 \| SAILIFE	5%	₹497 Cr	4,283,799
Trent Ltd (Consumer Cyclical) Equity, Since 28 Feb 22 \| TRENT	5%	₹460 Cr	1,089,122
Prestige Estates Projects Ltd (Real Estate) Equity, Since 31 Dec 23 \| PRESTIGE	4%	₹452 Cr	3,304,450 ↑ 174,545
ABB India Ltd (Industrials) Equity, Since 30 Jun 23 \| ABB	4%	₹441 Cr	608,622 ↑ 143,577
BSE Ltd (Financial Services) Equity, Since 31 Oct 23 \| BSE	4%	₹396 Cr	955,364 ↓ -149,234
L&T Finance Ltd (Financial Services) Equity, Since 30 Apr 24 \| LTF	3%	₹325 Cr	11,339,315

5. Motilal Oswal Focused 25 Fund

(Erstwhile Motilal Oswal MOSt Focused 25 Fund)

The investment objective of the Scheme is to achieve long term capital appreciation by investing in upto 25 companies with long term sustainable competitive advantage and growth potential. However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Research Highlights for Motilal Oswal Focused 25 Fund

Lower mid AUM (₹1,635 Cr).
Established history (13+ yrs).
Rating: 3★ (upper mid).
Risk profile: Moderately High.
5Y return: 9.70% (bottom quartile).
3Y return: 11.19% (bottom quartile).
1Y return: 14.20% (upper mid).
Alpha: 12.39 (top quartile).
Sharpe: 0.35 (lower mid).
Information ratio: -0.21 (bottom quartile).
Top sector: Financial Services.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Aditya Infotech Ltd (~4.9%).

Below is the key information for Motilal Oswal Focused 25 Fund

Motilal Oswal Focused 25 Fund Growth
Launch Date	7 May 13
NAV (29 Jul 26)	₹49.7399 ↑ 0.62 (1.26 %)
Net Assets (Cr)	₹1,635 on 30 Jun 26
Category	Equity - Focused
AMC	Motilal Oswal Asset Management Co. Ltd
Rating	☆☆☆
Risk	Moderately High
Expense Ratio	1.97
Sharpe Ratio	0.35
Information Ratio	-0.21
Alpha Ratio	12.39
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹9,256
30 Jun 23	₹11,328
30 Jun 24	₹14,505
30 Jun 25	₹13,885
30 Jun 26	₹15,417

Motilal Oswal Focused 25 Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹385,859.
Net Profit of ₹85,859 Invest Now

Returns for Motilal Oswal Focused 25 Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	2.3%
3 Month	11%
6 Month	17.9%
1 Year	14.2%
3 Year	11.2%
5 Year	9.7%
10 Year
15 Year
Since launch	12.9%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-1.7%
2024	13.6%
2023	18.8%
2022	2%
2021	14.6%
2020	17.3%
2019	17.1%
2018	-4.2%
2017	32.2%
2016	2.8%

Fund Manager information for Motilal Oswal Focused 25 Fund

Name	Since	Tenure
Varun Sharma	14 Aug 25	0.88 Yr.
Swapnil Mayekar	18 Nov 25	0.61 Yr.
Ankit Agarwal	5 Aug 25	0.9 Yr.
Rakesh Shetty	22 Nov 22	3.61 Yr.
Atul Mehra	1 Oct 24	1.75 Yr.

Data below for Motilal Oswal Focused 25 Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Financial Services	23.84%
Industrials	21.59%
Consumer Cyclical	17.2%
Technology	8.99%
Health Care	7.23%
Basic Materials	7.03%
Utility	3.18%
Communication Services	2.46%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Aditya Infotech Ltd (Industrials) Equity, Since 28 Feb 26 \| CPPLUS	5%	₹76 Cr	261,175
ICICI Prudential Asset Management Co Ltd (Financial Services) Equity, Since 31 Jan 26 \| ICICIAMC	4%	₹68 Cr	193,190 ↑ 8,826
Persistent Systems Ltd (Technology) Equity, Since 30 Apr 26 \| PERSISTENT	4%	₹66 Cr	127,008 ↑ 19,051
CG Power & Industrial Solutions Ltd (Industrials) Equity, Since 28 Feb 26 \| CGPOWER	4%	₹65 Cr	707,583 ↓ -71,782
AU Small Finance Bank Ltd (Financial Services) Equity, Since 31 Oct 25 \| AUBANK	4%	₹64 Cr	645,708 ↑ 40,286
Eternal Ltd (Consumer Cyclical) Equity, Since 31 Jan 26 \| ETERNAL	4%	₹63 Cr	2,529,956 ↑ 118,365
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 28 Feb 26 \| APOLLOHOSP	4%	₹62 Cr	75,565 ↑ 4,721
Gabriel India Ltd (Consumer Cyclical) Equity, Since 31 Aug 25 \| GABRIEL	4%	₹59 Cr	536,227
Aditya Vision Ltd (Consumer Cyclical) Equity, Since 30 Sep 25 \| 540205	4%	₹55 Cr	1,020,017
ABB India Ltd (Industrials) Equity, Since 31 May 26 \| ABB	3%	₹54 Cr	74,566 ↑ 74,566

ટોચના 5 હોટ મ્યુચ્યુઅલ ફંડ્સ 6 મહિના

નેટ અસ્કયામતો ધરાવતા શ્રેષ્ઠ મ્યુચ્યુઅલ ફંડોની યાદી નીચે છે100 કરોડ અને છેલ્લા 6 મહિનામાં શ્રેષ્ઠ વળતર આપ્યું છે.

1. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

Research Highlights for SBI Healthcare Opportunities Fund

Upper mid AUM (₹4,998 Cr).
Established history (21+ yrs).
Rating: 2★ (upper mid).
Risk profile: High.
5Y return: 17.42% (top quartile).
3Y return: 23.05% (upper mid).
1Y return: 15.20% (top quartile).
Alpha: 2.23 (upper mid).
Sharpe: 0.59 (top quartile).
Information ratio: -0.17 (lower mid).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~97%).
High-quality debt (AAA/AA ~100%).
Largest holding Sun Pharmaceuticals Industries Ltd (~11.0%).

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund Growth
Launch Date	31 Dec 04
NAV (29 Jul 26)	₹512.59 ↑ 6.51 (1.29 %)
Net Assets (Cr)	₹4,998 on 30 Jun 26
Category	Equity - Sectoral
AMC	SBI Funds Management Private Limited
Rating	☆☆
Risk	High
Expense Ratio	1.97
Sharpe Ratio	0.59
Information Ratio	-0.17
Alpha Ratio	2.23
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,662
30 Jun 23	₹11,165
30 Jun 24	₹15,491
30 Jun 25	₹18,739
30 Jun 26	₹21,357

SBI Healthcare Opportunities Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047 Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	4.7%
3 Month	17%
6 Month	27.4%
1 Year	15.2%
3 Year	23%
5 Year	17.4%
10 Year
15 Year
Since launch	15.7%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-3.5%
2024	42.2%
2023	38.2%
2022	-6%
2021	20.1%
2020	65.8%
2019	-0.5%
2018	-9.9%
2017	2.1%
2016	-14%

Fund Manager information for SBI Healthcare Opportunities Fund

Name	Since	Tenure
Tanmaya Desai	1 Jun 11	15.09 Yr.

Data below for SBI Healthcare Opportunities Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	88.67%
Basic Materials	8.82%

Asset Allocation

Asset Class	Value
Cash	2.45%
Equity	97.49%
Debt	0.06%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Dec 17 \| SUNPHARMA	11%	₹504 Cr	2,800,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	7%	₹300 Cr	450,000
Acutaas Chemicals Ltd (Basic Materials) Equity, Since 30 Jun 24 \| 543349	6%	₹282 Cr	900,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Jan 26 \| APOLLOHOSP	5%	₹245 Cr	300,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 21 \| MAXHEALTH	5%	₹217 Cr	2,250,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Mar 26 \| AUROPHARMA	4%	₹178 Cr	1,250,000 ↑ 250,000
Aster DM Healthcare Ltd Ordinary Shares (Healthcare) Equity, Since 31 Mar 24 \| ASTERDM	4%	₹175 Cr	2,400,000
Laurus Labs Ltd (Healthcare) Equity, Since 31 Aug 23 \| LAURUSLABS	4%	₹163 Cr	1,200,000
Biocon Ltd (Healthcare) Equity, Since 30 Nov 24 \| BIOCON	4%	₹161 Cr	3,750,000
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Jun 21 \| TORNTPHARM	3%	₹159 Cr	360,000

2. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

Research Highlights for UTI Healthcare Fund

Bottom quartile AUM (₹1,308 Cr).
Oldest track record among peers (27 yrs).
Rating: 1★ (lower mid).
Risk profile: High.
5Y return: 15.05% (bottom quartile).
3Y return: 23.43% (top quartile).
1Y return: 12.09% (upper mid).
Alpha: 2.15 (lower mid).
Sharpe: 0.58 (upper mid).
Information ratio: 0.20 (top quartile).
Higher exposure to Health Care vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~94%).
Largest holding Sun Pharmaceuticals Industries Ltd (~8.9%).

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund Growth
Launch Date	28 Jun 99
NAV (29 Jul 26)	₹335.233 ↑ 4.62 (1.40 %)
Net Assets (Cr)	₹1,308 on 30 Jun 26
Category	Equity - Sectoral
AMC	UTI Asset Management Company Ltd
Rating	☆
Risk	High
Expense Ratio	2.26
Sharpe Ratio	0.58
Information Ratio	0.2
Alpha Ratio	2.15
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,478
30 Jun 23	₹10,006
30 Jun 24	₹14,264
30 Jun 25	₹17,337
30 Jun 26	₹19,764

UTI Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹447,579.
Net Profit of ₹147,579 Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	3.9%
3 Month	14.6%
6 Month	24.8%
1 Year	12.1%
3 Year	23.4%
5 Year	15.1%
10 Year
15 Year
Since launch	15%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-3.1%
2024	42.9%
2023	38.2%
2022	-12.3%
2021	19.1%
2020	67.4%
2019	1.2%
2018	-7.5%
2017	6.2%
2016	-9.7%

Fund Manager information for UTI Healthcare Fund

Name	Since	Tenure
Kamal Gada	2 May 22	4.17 Yr.

Data below for UTI Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	94.45%

Asset Allocation

Asset Class	Value
Cash	5.55%
Equity	94.45%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 06 \| SUNPHARMA	9%	₹108 Cr	600,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	5%	₹59 Cr	88,814 ↑ 28,076
Ajanta Pharma Ltd (Healthcare) Equity, Since 31 Jul 17 \| AJANTPHARM	5%	₹57 Cr	195,295 ↓ -41,216
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	4%	₹48 Cr	215,251
Lupin Ltd (Healthcare) Equity, Since 28 Feb 25 \| LUPIN	4%	₹46 Cr	203,834 ↓ -6,166
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Apr 21 \| APOLLOHOSP	4%	₹43 Cr	53,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 28 Feb 18 \| DRREDDY	3%	₹38 Cr	290,000
Caplin Point Laboratories Ltd (Healthcare) Equity, Since 31 Dec 23 \| CAPLIPOINT	3%	₹37 Cr	185,000 ↑ 39,847
Alkem Laboratories Ltd (Healthcare) Equity, Since 31 May 21 \| ALKEM	3%	₹37 Cr	68,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Dec 20 \| FORTIS	3%	₹37 Cr	400,000

3. IDBI Small Cap Fund

The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing predominantly in Equity and Equity related instruments of Small Cap companies. However there can be no assurance that the investment objective under the Scheme will be realized.

Research Highlights for IDBI Small Cap Fund

Bottom quartile AUM (₹743 Cr).
Established history (9+ yrs).
Not Rated.
Risk profile: Moderately High.
5Y return: 16.96% (upper mid).
3Y return: 16.82% (bottom quartile).
1Y return: 8.12% (bottom quartile).
Alpha: 9.18 (top quartile).
Sharpe: 0.27 (lower mid).
Information ratio: -0.23 (bottom quartile).
Higher exposure to Industrials vs peer median.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~98%).
Largest holding Garware Hi-Tech Films Ltd (~5.1%).

Below is the key information for IDBI Small Cap Fund

IDBI Small Cap Fund Growth
Launch Date	21 Jun 17
NAV (29 Jul 26)	₹33.2249 ↑ 0.25 (0.75 %)
Net Assets (Cr)	₹743 on 30 Jun 26
Category	Equity - Small Cap
AMC	IDBI Asset Management Limited
Rating	Not Rated
Risk	Moderately High
Expense Ratio	2.3
Sharpe Ratio	0.27
Information Ratio	-0.23
Alpha Ratio	9.18
Min Investment	5,000
Min SIP Investment	500
Exit Load	0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹10,917
30 Jun 23	₹14,083
30 Jun 24	₹21,728
30 Jun 25	₹21,091
30 Jun 26	₹23,146

IDBI Small Cap Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689 Invest Now

Returns for IDBI Small Cap Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	-0.3%
3 Month	8.3%
6 Month	21.5%
1 Year	8.1%
3 Year	16.8%
5 Year	17%
10 Year
15 Year
Since launch	14.1%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-13.4%
2024	40%
2023	33.4%
2022	2.4%
2021	64.7%
2020	19%
2019	-4.4%
2018	-15%
2017
2016

Fund Manager information for IDBI Small Cap Fund

Name	Since	Tenure
Dikshit Mittal	24 Jul 25	0.93 Yr.
Mahesh Bendre	1 Jul 24	2 Yr.

Data below for IDBI Small Cap Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Industrials	27.58%
Basic Materials	16.22%
Consumer Cyclical	14.1%
Financial Services	11.08%
Consumer Defensive	9.75%
Health Care	6.95%
Technology	6.46%
Utility	2.92%
Real Estate	1.49%
Communication Services	0.98%

Asset Allocation

Asset Class	Value
Cash	2.48%
Equity	97.52%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Garware Hi-Tech Films Ltd (Basic Materials) Equity, Since 30 Sep 25 \| 500655	5%	₹36 Cr	58,461 ↓ -1,326
Avalon Technologies Ltd (Technology) Equity, Since 31 Aug 23 \| AVALON	4%	₹26 Cr	167,845 ↓ -3,517
Navin Fluorine International Ltd (Basic Materials) Equity, Since 30 Sep 19 \| NAVINFLUOR	3%	₹21 Cr	29,286
Manorama Industries Ltd (Consumer Defensive) Equity, Since 31 Dec 24 \| 541974	3%	₹20 Cr	142,461 ↑ 22,179
KSH International Ltd (Industrials) Equity, Since 31 Dec 25 \| KSHINTL	3%	₹18 Cr	233,215 ↓ -16,165
Allied Blenders and Distillers Ltd (Consumer Defensive) Equity, Since 31 Jul 24 \| ABDL	3%	₹18 Cr	326,615
Schneider Electric Infrastructure Ltd (Industrials) Equity, Since 31 Aug 25 \| SCHNEIDER	3%	₹17 Cr	133,576
Arvind Fashions Ltd (Consumer Cyclical) Equity, Since 29 Feb 24 \| ARVINDFASN	2%	₹17 Cr	361,684 ↑ 53,437
Kirloskar Oil Engines Ltd (Industrials) Equity, Since 28 Feb 21 \| 533293	2%	₹15 Cr	78,792
Pricol Ltd (Consumer Cyclical) Equity, Since 30 Sep 25 \| PRICOLLTD	2%	₹13 Cr	237,103 ↑ 23,351

4. DSP Small Cap Fund

(Erstwhile DSP BlackRock Micro Cap Fund)

The primary investment objective is to seek to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of small cap companies. From time to time, the fund manager will also seek participation in other equity and equity related securities to achieve optimal portfolio construction. There is no assurance that the investment objective of the Scheme will be realized

Research Highlights for DSP Small Cap Fund

Highest AUM (₹19,635 Cr).
Established history (19+ yrs).
Top rated.
Risk profile: Moderately High.
5Y return: 16.60% (lower mid).
3Y return: 16.83% (bottom quartile).
1Y return: 10.32% (lower mid).
Alpha: 0.00 (bottom quartile).
Sharpe: 0.19 (bottom quartile).
Information ratio: 0.00 (upper mid).
Higher exposure to Consumer Cyclical vs peer median.
Higher exposure to Cash Equivalent (bond sector) vs peer median.
Equity-heavy allocation (~90%).
Largest holding Lumax Auto Technologies Ltd (~5.0%).

Below is the key information for DSP Small Cap Fund

DSP Small Cap Fund Growth
Launch Date	14 Jun 07
NAV (29 Jul 26)	₹221.917 ↑ 0.99 (0.45 %)
Net Assets (Cr)	₹19,635 on 30 Jun 26
Category	Equity - Small Cap
AMC	DSP BlackRock Invmt Managers Pvt. Ltd.
Rating	☆☆☆☆
Risk	Moderately High
Expense Ratio	1.72
Sharpe Ratio	0.19
Information Ratio	0
Alpha Ratio	0
Min Investment	1,000
Min SIP Investment	500
Exit Load	0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹10,594
30 Jun 23	₹13,804
30 Jun 24	₹19,548
30 Jun 25	₹21,421
30 Jun 26	₹23,103

DSP Small Cap Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689 Invest Now

Returns for DSP Small Cap Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	2.9%
3 Month	9.3%
6 Month	21%
1 Year	10.3%
3 Year	16.8%
5 Year	16.6%
10 Year
15 Year
Since launch	17.6%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-2.8%
2024	25.6%
2023	41.2%
2022	0.5%
2021	58.9%
2020	33.1%
2019	0.7%
2018	-25.5%
2017	42.8%
2016	12.7%

Fund Manager information for DSP Small Cap Fund

Name	Since	Tenure
Vinit Sambre	21 Jun 10	16.04 Yr.

Data below for DSP Small Cap Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Consumer Cyclical	31.79%
Industrials	16.23%
Basic Materials	15.28%
Health Care	9.25%
Financial Services	8.24%
Consumer Defensive	6.15%
Technology	2.11%
Communication Services	0.44%

Asset Allocation

Asset Class	Value
Cash	10.5%
Equity	89.5%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Lumax Auto Technologies Ltd (Consumer Cyclical) Equity, Since 30 Jun 18 \| LUMAXTECH	5%	₹921 Cr	5,337,441 ↓ -600,000
Kirloskar Oil Engines Ltd (Industrials) Equity, Since 31 Mar 23 \| 533293	4%	₹725 Cr	3,762,866
Thangamayil Jewellery Ltd (Consumer Cyclical) Equity, Since 30 Nov 21 \| THANGAMAYL	3%	₹628 Cr	1,493,620 ↓ -91,335
Sansera Engineering Ltd (Consumer Cyclical) Equity, Since 30 Jun 24 \| SANSERA	3%	₹506 Cr	1,770,029
Welspun Corp Ltd (Basic Materials) Equity, Since 31 Mar 21 \| WELCORP	3%	₹470 Cr	3,411,788 ↓ -343,883
Jubilant Ingrevia Ltd Ordinary Shares (Basic Materials) Equity, Since 31 Dec 22 \| JUBLINGREA	2%	₹450 Cr	6,970,677 ↓ -29,323
Dodla Dairy Ltd (Consumer Defensive) Equity, Since 30 Jun 21 \| DODLA	2%	₹405 Cr	3,750,000
LT Foods Ltd (Consumer Defensive) Equity, Since 31 Dec 17 \| LTFOODS	2%	₹392 Cr	10,000,000
SPR Auto Technologies Ltd (Consumer Cyclical) Equity, Since 31 Aug 24 \| SHRIPISTON	2%	₹367 Cr	1,081,165
eClerx Services Ltd (Technology) Equity, Since 28 Feb 18 \| ECLERX	2%	₹334 Cr	2,211,836

5. TATA India Pharma & Healthcare Fund

Research Highlights for TATA India Pharma & Healthcare Fund

Lower mid AUM (₹1,455 Cr).
Established history (10+ yrs).
Not Rated.
Risk profile: High.
5Y return: 14.11% (bottom quartile).
3Y return: 19.49% (lower mid).
1Y return: 8.02% (bottom quartile).
Alpha: -7.90 (bottom quartile).
Sharpe: 0.16 (bottom quartile).
Information ratio: -0.61 (bottom quartile).
Top sector: Health Care.
Top bond sector: Cash Equivalent.
Equity-heavy allocation (~99%).
Largest holding Sun Pharmaceuticals Industries Ltd (~9.4%).

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund Growth
Launch Date	28 Dec 15
NAV (29 Jul 26)	₹33.7302 ↑ 0.32 (0.97 %)
Net Assets (Cr)	₹1,455 on 30 Jun 26
Category	Equity - Sectoral
AMC	Tata Asset Management Limited
Rating	Not Rated
Risk	High
Expense Ratio	2.17
Sharpe Ratio	0.16
Information Ratio	-0.61
Alpha Ratio	-7.9
Min Investment	5,000
Min SIP Investment	150
Exit Load	0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

Date	Value
30 Jun 21	₹10,000
30 Jun 22	₹8,951
30 Jun 23	₹10,628
30 Jun 24	₹15,238
30 Jun 25	₹17,550
30 Jun 26	₹18,791

TATA India Pharma & Healthcare Fund SIP Returns

Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710 Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 29 Jul 26

Duration	Returns
1 Month	5.3%
3 Month	12.5%
6 Month	19.4%
1 Year	8%
3 Year	19.5%
5 Year	14.1%
10 Year
15 Year
Since launch	12.2%

Historical performance (Yearly) on absolute basis

Year	Returns
2025	-4.9%
2024	40.4%
2023	36.6%
2022	-8%
2021	19.1%
2020	64.4%
2019	5.5%
2018	-2.6%
2017	4.7%
2016	-14.7%

Fund Manager information for TATA India Pharma & Healthcare Fund

Name	Since	Tenure
Rajat Srivastava	16 Sep 24	1.79 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 30 Jun 26

Equity Sector Allocation

Sector	Value
Health Care	93.6%
Basic Materials	3.96%
Consumer Defensive	1.35%
Financial Services	0.4%

Asset Allocation

Asset Class	Value
Cash	0.7%
Equity	99.3%

Top Securities Holdings / Portfolio

Name	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Jan 16 \| SUNPHARMA	9%	₹130 Cr	723,130
HealthCare Global Enterprises Ltd (Healthcare) Equity, Since 31 Dec 18 \| HCG	6%	₹81 Cr	1,276,727 ↑ 15,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 30 Sep 17 \| DIVISLAB	6%	₹80 Cr	120,600
Abbott India Ltd (Healthcare) Equity, Since 30 Sep 25 \| ABBOTINDIA	5%	₹75 Cr	27,953
Cipla Ltd (Healthcare) Equity, Since 30 Apr 20 \| CIPLA	5%	₹72 Cr	512,754
Max Healthcare Institute Ltd Ordinary Shares (Healthcare) Equity, Since 31 Jul 25 \| MAXHEALTH	5%	₹67 Cr	690,488
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 31 Dec 16 \| APOLLOHOSP	5%	₹63 Cr	77,345 ↑ 6,861
Rainbow Childrens Medicare Ltd (Healthcare) Equity, Since 31 Jul 25 \| 543524	5%	₹63 Cr	454,338 ↑ 7,205
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 31 Aug 18 \| DRREDDY	4%	₹56 Cr	428,116 ↑ 54,652
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	4%	₹52 Cr	220,018

મ્યુચ્યુઅલ ફંડમાં ઓનલાઈન કેવી રીતે રોકાણ કરવું?

Fincash.com પર આજીવન માટે મફત રોકાણ ખાતું ખોલો.

તમારી નોંધણી અને KYC પ્રક્રિયા પૂર્ણ કરો

દસ્તાવેજો અપલોડ કરો (PAN, આધાર, વગેરે).અને, તમે રોકાણ કરવા માટે તૈયાર છો!

શરૂ કરો

Disclaimer:
અહીં આપેલી માહિતી સચોટ છે તેની ખાતરી કરવા માટેના તમામ પ્રયાસો કરવામાં આવ્યા છે. જો કે, ડેટાની શુદ્ધતા અંગે કોઈ ગેરંટી આપવામાં આવતી નથી. કોઈપણ રોકાણ કરતા પહેલા કૃપા કરીને સ્કીમ માહિતી દસ્તાવેજ સાથે ચકાસો.